OBJECTIVE: The objective of this study was to estimate resource utilization and expenditures for patients with acute myeloid leukemia (AML) in a real-world claims database. RESEARCH DESIGN AND METHODS: AML patients were identified in MarketScan claims databases between 1 January 2009 and 31 January 2015. Patients had a minimum of two AML diagnosis codes, hospitalization within 14 days after initial diagnosis, and ≥6 months of enrollment before initial diagnosis. Patients were monitored from first-line induction to a record of remission. A subset had a record of a second treatment period, defined as time from relapse to remission. Patient demographics, AML risk factors, and comorbidities were recorded. Descriptive analysis of utilization and expenditures (in 2014 $US) were reported for each cohort. RESULTS: The inclusion criteria were met in 1597 patients (mean age, 58.4 years; 51.0% male). Ninety percent of patients had ≥1 risk factor for AML. Mean (SD) healthcare expenditures for patients from first-line induction to remission (n = 681) were $208,857 ($152,090). Of the 157 who had a record of relapse, 70 had a record of a second remission. Expenditures for these patients (n = 70) from relapse to remission were $142,569 ($208,307); 60% were admitted to a hospital for a mean of 18.5 hospital days, and 20% had ≥1 emergency room visit. CONCLUSIONS: Although this claims-based analysis is limited by a lack of generalizability to noninsured populations and potential underreporting of certain events and diagnoses, we found that treating AML patients poses a significant healthcare burden, during both first-line induction and relapse. With people living longer, the number of cases of AML is expected to increase in the future.
OBJECTIVE: The objective of this study was to estimate resource utilization and expenditures for patients with acute myeloid leukemia (AML) in a real-world claims database. RESEARCH DESIGN AND METHODS: AMLpatients were identified in MarketScan claims databases between 1 January 2009 and 31 January 2015. Patients had a minimum of two AML diagnosis codes, hospitalization within 14 days after initial diagnosis, and ≥6 months of enrollment before initial diagnosis. Patients were monitored from first-line induction to a record of remission. A subset had a record of a second treatment period, defined as time from relapse to remission. Patient demographics, AML risk factors, and comorbidities were recorded. Descriptive analysis of utilization and expenditures (in 2014 $US) were reported for each cohort. RESULTS: The inclusion criteria were met in 1597 patients (mean age, 58.4 years; 51.0% male). Ninety percent of patients had ≥1 risk factor for AML. Mean (SD) healthcare expenditures for patients from first-line induction to remission (n = 681) were $208,857 ($152,090). Of the 157 who had a record of relapse, 70 had a record of a second remission. Expenditures for these patients (n = 70) from relapse to remission were $142,569 ($208,307); 60% were admitted to a hospital for a mean of 18.5 hospital days, and 20% had ≥1 emergency room visit. CONCLUSIONS: Although this claims-based analysis is limited by a lack of generalizability to noninsured populations and potential underreporting of certain events and diagnoses, we found that treating AMLpatients poses a significant healthcare burden, during both first-line induction and relapse. With people living longer, the number of cases of AML is expected to increase in the future.
Authors: Jan Philipp Bewersdorf; Kishan K Patel; George Goshua; Rory M Shallis; Nikolai A Podoltsev; Scott F Huntington; Amer M Zeidan Journal: Blood Date: 2022-03-17 Impact factor: 22.113
Authors: Emma Hernlund; Josefine Redig; Björn Paulsson; Åsa Rangert Derolf; Martin Höglund; Simona Vertuani; Gunnar Juliusson Journal: EJHaem Date: 2021-05-06
Authors: Bhavik J Pandya; Chi-Chang Chen; Bruno C Medeiros; Catherine B McGuiness; Samuel Wilson; L Elise Horvath Walsh; Rolin L Wade Journal: Adv Ther Date: 2019-06-20 Impact factor: 3.845
Authors: James D Griffin; Hongbo Yang; Yan Song; David Kinrich; Manasee V Shah; Cat N Bui Journal: Eur J Haematol Date: 2019-02-05 Impact factor: 2.997
Authors: Antonio Solana-Altabella; Juan Eduardo Megías-Vericat; Octavio Ballesta-López; Blanca Boluda; Isabel Cano; Evelyn Acuña-Cruz; Rebeca Rodríguez-Veiga; Laura Torres-Miñana; Claudia Sargas; Miguel Á Sanz; Carmela Borrell-García; Eduardo López-Briz; José Luis Poveda-Andrés; Javier De la Rubia; Pau Montesinos; David Martínez-Cuadrón Journal: Cancers (Basel) Date: 2022-04-11 Impact factor: 6.639